ClinActiv Holdings Inc. has completed a plan of arrangement to acquire all issued and outstanding common shares of Crescita Therapeutics Inc. [1]
This acquisition consolidates the ownership of Crescita Therapeutics, moving the company under the umbrella of ClinActiv's subsidiary. The move signals a transition in corporate structure for the therapeutics firm, which is headquartered in Laval, Québec [2].
The transaction follows a series of corporate governance steps initiated earlier this year. The process included a special meeting of shareholders held May 14, 2026 [3]. This meeting was part of the formal requirements to approve the plan of arrangement that allowed the Purchaser, a wholly-owned subsidiary of ClinActiv, to take full control of the company's equity [1].
To determine the eligibility for the vote, the company established a shareholders of record date as the close of business April 9, 2026 [3]. This timeline ensured that all eligible stakeholders were identified before the final acquisition steps were executed this month.
Crescita Therapeutics operates from its head office located at 2805 Place Louis‑R‑Renaud in Laval, Québec [2]. The closing of the arrangement marks the final stage of the previously announced plan to integrate the two entities [1].
While the specific financial terms of the closing were not detailed in the immediate announcement, the completion of the arrangement means that all outstanding common shares have been transferred to the Purchaser [1]. This concludes the legal transition of the company's ownership and governance structure.
“ClinActiv Holdings Inc. has completed a plan of arrangement to acquire all issued and outstanding common shares of Crescita Therapeutics Inc.”
The acquisition of Crescita Therapeutics by ClinActiv Holdings represents a strategic consolidation of assets within the biotechnology or pharmaceutical sector. By moving from a publicly traded or independently held structure to becoming a subsidiary, Crescita may benefit from ClinActiv's broader resources and capital, though it loses its independent corporate identity.
